研究单位：[1]Klus Pharma Inc.[2]Anderson Cancer Center[3]University of California Los Angeles,Los Angeles,California,United States,90404[4]Georgetown University,Washington,District of Columbia,United States,20057[5]Florida Cancer Specialists and Research Institute,Sarasota,Florida,United States,34232[6]Beth Israel Deaconess Medical Center,Boston,Massachusetts,United States,02215[7]START MidWest,Grand Rapids,Michigan,United States,49546[8]The University of Oklahoma Health Sciences Center,Oklahoma City,Oklahoma,United States,73104[9]Providence Cancer Institute, Franz Clinic,Portland,Oregon,United States,97213[10]Mary Crowley Cancer Research,Dallas,Texas,United States,75230[11]MD Anderson Cancer Center,Houston,Texas,United States,77030[12]Virginia Cancer Specialists,Fairfax,Virginia,United States,22031[13]The Second Hospital of Anhui Medical University,Hefei,Anhui,China[14]Chongqing University Cancer Hosptital,Chongqing,Chongqing,China[15]The First Affiliated Hospital Of Xiamen University,Xiamen,Fujian,China[16]Sun Yat-sen University Cancer Center,Guangzhou,Guangzhou,China[17]Zhejiang Cancer Hospital,Gongshu,Hangzhou,China[18]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China[19]Wuhan Union Hospital of China,Wuhan,Hubei,China[20]Hunan Cancer Hospital,Changsha,Hunan,China[21]Shandong Cancer Hospital,Jinan,Shandong,China[22]West China Hospital of Sichuan University,Chengdu,Sichuan,China[23]Hubei Cancer Hospital,Hongshan,Wuhan,China[24]The First Affiliated Hospital, Zhejiang University School of Medicine,Hangzhou,Zhejiang,China[25]Zhejiang Cancer Hospital,Hangzhou,Zhejiang,China[26]ZHEJIANG University School of Medical SIR RUN RUN SHAW Hospital,Hangzhou,Zhejiang,China[27]Beijing Cancer Hospital,Beijing,China[28]Beijing Cancer Hospital,Beijing,China[29]Beijing Chao-Yang Hospital, Capital Medical University,Beijing,China[30]Chinese PLA General Hospital (301 Hospital),Beijing,China[31]Jilin Cancer Hospital,Changchun,China[32]Hunan Cancer Hospital,Changsha,China[33]Sichuan Cancer Hospital,Chengdu,China[34]Chongqing University Cancer Hospital,Chongqing,China[35]The Second Hospital of Dalian Medical University,Dalian,China[36]Sun Yat-Sen Memorial Hospital , Sun Yat-sen University,Guangzhou,China[37]Harbin Medical University Cancer Hospital,Harbin,China[38]Hunan Cancer Hospital,Hunan,China[39]Jiangxi Cancer Hospital,Nanchang,China[40]The First Affiliated Hospital of Nanchang University,Nanchang,China[41]Jiangsu Province Hospital,Nanjing,China[42]Shandong Cancer Hospital,Shandong,China[43]Fudan University Shanghai Cancer Center,Shanghai,China[44]Shanghai East Hospital,Shanghai,China[45]Zhongshan Hospital, Fudan University,Shanghai,China[46]Liaoning Cancer Hospital,Shenyang,China[47]The First Hospital of China Medical University,Shenyang,China[48]The Fourth Hospital of Hebei Medical University,Shijiazhuang,China[49]Shanxi Provincial Cancer Hospital,Taiyuan,China[50]Tianjin Cancer Hospital,Tianjin,China[51]Tianjin Medical University Cancer,Tianjin,China[52]Weifang People's Hospital,Weifang,China[53]Hubei Cancer Hospital,Wuhan,China[54]Wuhan Union Hospital of China,Wuhan,China[55]Zhongnan Hospital of Wuhan University,Wuhan,China[56]The First Affiliated Hospital of Xi''an Jiaotong University,Xi''an,China[57]Xuzhou Central Hospital,Xuzhou,China[58]Henan Cancer Hospital,Zhengzhou,China
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types: 1. Triple negative breast cancer 2. Epithelial ovarian cancer 3. Non-small cell lung cancer 4. Gastric adenocarcinoma/Gastroesophageal junction adenocarcinoma 5. Small cell lung cancer 6. HR+/ HER2-breast cancer 7. Head and neck squamous cell carcinoma 8. Endometrial carcinoma 9. Urothelial carcinoma
